<DOC>
	<DOCNO>NCT01939197</DOCNO>
	<brief_summary>The purpose study assess safety efficacy ombitasvir/paritaprevir/ritonavir without dasabuvir coadministered without ribavirin 12 24 week adults genotype 1 4 Chronic Hepatitis C Virus Infection Human Immunodeficiency Virus , Type 1 coinfection .</brief_summary>
	<brief_title>A Two Part , Open-label Study Evaluate Safety Effectiveness ABT-450/r/ABT-267 ABT-450/r/ABT-267 ABT-333 Given With Without Drug Called Ribavirin People With Both Hepatitis C Virus Genotype 1 4 Infection Human Immunodeficiency Virus , Type 1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Chronic HCV infection Screening define : Positive antiHCV Ab Screening HCV RNA &gt; 1,000 IU/mL Screening . Plasma HIV1 RNA &lt; 40 copies/mL Screening use Abbott RealTime HIV1 assay . On stable qualify human immunodeficiency virus , type 1 ( HIV1 ) antiretroviral therapy regimen . Positive test result screen Hepatitis B surface antigen . Evidence HCV genotype genotype 1 genotype 4 screening . Receipt investigational commercially available antiHCV agent ( example , telaprevir , boceprevir , simeprevir , daclatasvir ledipasvir ) exception interferon ( include pegylatedinterferon alfa2a alfa2b ) , sofosbuvir ribavirin . Consideration investigator , reason , subject unsuitable candidate receive ABT450 , ABT267 , ABT333 , ritonavir ribavirin . Chronic human immunodeficiency virus , type 2 ( HIV2 ) infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Cirrhotic</keyword>
	<keyword>HCV Genotype 4</keyword>
	<keyword>Hepatitis C Genotype 1</keyword>
	<keyword>HCV Genotype 1</keyword>
	<keyword>Compensated Cirrhosis</keyword>
	<keyword>Hepatitis C Genotype 4</keyword>
	<keyword>Interferon-Free</keyword>
	<keyword>HIV-1</keyword>
	<keyword>HCV / HIV coinfection</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>